2-Bromo-4-trifluoromethoxyaniline

We are 2-Bromo-4-trifluoromethoxyaniline CAS:175278-17-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2-Bromo-4-trifluoromethoxyaniline
CAS.NO:175278-17-8
Synonyms:2-Bromo-4-trifluoromethoxyaniline
2-bromo-4-trifluoromethoxy-phenylamine
2-bromo-4-(trifluoromethyloxy)aniline
4-(trifluoromethoxy)-2-bromoaniline
2-Bromo-4-Trifluoromethoxyaniline
Molecular Formula:C7H5BrF3NO
Molecular Weight:256.02000
 
Physical and Chemical Properties:
Density:1.693
Boiling point:209ºC
Flash point:>230°F
Index of Refraction:1.504
 
Specification:
Appearance:Light yellow to orange-yellow clear liquid
Assay:≥98.0%
Moisture:≤0.5%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate

2-Bromo-4-trifluoromethoxyaniline


Related News: This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.195730-47-3 This requires enterprises to have high R & D strength and strategic foresight, keep reserves projects, and seize the market after patents expire.437-81-0 At present, the additional 300 tons of sunniamine, 300 tons of fluoxamic acid, and 200 tons of cyprodinil have been successfully put into production, and the profitability is good.Ácido 6-cloronicotínico CAS:5326-23-8 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.

Related Products
Product Name
4-((4-Methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline View Details
7-Methoxy-1-tetralone View Details
7-hydroxy-1H-quinolin-2-one View Details
4,4,5,5,5-Pentafluoro-1-pentanol manufacturer 2-Bromobutane manufacturer 1-(3,4-dihydro-2H-pyrrol-2-yl)ethanone manufacturer 4-Hydroxy-3-methoxybenzylamine hydrochloride manufacturer Nα,Nε-Di-Boc-L-lysine Dicyclohexylammonium Salt manufacturer